Karen S. Britt

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 163 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent

Hongyu Li, William T. McMillen, Charles R. Heap et al. · Journal of Medicinal Chemistry · 2008 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors:  A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7

Hongyu Li, Yan Wang, Charles R. Heap et al. · Journal of Medicinal Chemistry · 2006 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

Huaxing Pei, Saravanan Parthasarathy, Sajan Joseph et al. · Cancer Research · 2017 · 29 citations

Medicine, Oncology, Pharmacology +16